These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 36762258)
1. Changes of Gut Microbiome in Adolescent Patients with Chronic Spontaneous Urticaria After Omalizumab Treatment. Wang M; Zhao L; Wang K; Qin Y; Jin J; Wang D; Yan H; You C Clin Cosmet Investig Dermatol; 2023; 16():345-357. PubMed ID: 36762258 [TBL] [Abstract][Full Text] [Related]
2. Abnormalities in Gut Microbiota and Metabolism in Patients With Chronic Spontaneous Urticaria. Wang X; Yi W; He L; Luo S; Wang J; Jiang L; Long H; Zhao M; Lu Q Front Immunol; 2021; 12():691304. PubMed ID: 34721374 [TBL] [Abstract][Full Text] [Related]
3. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome. Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702 [TBL] [Abstract][Full Text] [Related]
4. Gut Microbiome Alterations and Functional Prediction in Chronic Spontaneous Urticaria Patients. Zhang X; Zhang J; Chu Z; Shi L; Geng S; Guo K J Microbiol Biotechnol; 2021 May; 31(5):747-755. PubMed ID: 33746191 [TBL] [Abstract][Full Text] [Related]
5. Combined microbiome and metabolome analysis of gut microbiota and metabolite interactions in chronic spontaneous urticaria. Luo Z; Jin Z; Tao X; Wang T; Wei P; Zhu C; Wang Z Front Cell Infect Microbiol; 2022; 12():1094737. PubMed ID: 36710970 [TBL] [Abstract][Full Text] [Related]
6. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response. Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW; Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Chronic Spontaneous Urticaria with a Single Dose of Omalizumab: A Study of Four Cases. Subramaniyan R; Chopra A Indian J Dermatol; 2016; 61(4):467. PubMed ID: 27512204 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464 [No Abstract] [Full Text] [Related]
9. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study. Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483 [TBL] [Abstract][Full Text] [Related]
10. Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome. Chen J; Ou S; Wu W; Zou H; Li H; Zhu H Clin Cosmet Investig Dermatol; 2024; 17():1799-1808. PubMed ID: 39132026 [TBL] [Abstract][Full Text] [Related]
11. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria. Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. Hide M; Igarashi A; Yagami A; Chinuki Y; Inomata N; Fukunaga A; Kaiser G; Wang J; Matsushima S; Greenberg S; Khalil S Allergol Int; 2018 Apr; 67(2):243-252. PubMed ID: 29102514 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study. Ghazanfar MN; Holm JG; Thomsen SF J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103 [TBL] [Abstract][Full Text] [Related]
14. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience. Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A; Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719 [TBL] [Abstract][Full Text] [Related]
15. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria. Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395 [TBL] [Abstract][Full Text] [Related]
16. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325 [TBL] [Abstract][Full Text] [Related]
17. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both. Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832 [TBL] [Abstract][Full Text] [Related]
18. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. Asero R; Marzano AV; Ferrucci S; Lorini M; Carbonelli V; Cugno M Clin Exp Immunol; 2020 Jun; 200(3):242-249. PubMed ID: 32115683 [TBL] [Abstract][Full Text] [Related]
19. Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies. Mandel VD; Guanti MB; Liberati S; Demonte A; Pellacani G; Pepe P Dermatol Ther (Heidelb); 2018 Jun; 8(2):291-301. PubMed ID: 29770909 [TBL] [Abstract][Full Text] [Related]
20. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease. Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F Front Immunol; 2021; 12():635069. PubMed ID: 33737936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]